Pharmacokinetics of cerivastatin in renal impairment are predicted by low serum albumin concentration rather than by low creatinine clearance

Journal of Clinical Pharmacology

Volumn 39, Issue 2, 1999, Pages 147-154

  Vormfelde, Stefan Viktor ^b   Mück, Wolfgang ^a   Freudenthaler, Stefan M ^c   Heyen, Petra ^a   Schmage, Nikolaus ^a   Kuhlmann, Jochen ^a   Müller, Gerhard A ^c   Gundert Remy, Ursula M ^c   Gleiter, Christoph H ^c  

^a BAYER AG   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CERIVASTATIN; CREATININE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY DISEASE; MALE; ORAL DRUG ADMINISTRATION; PREDICTION;

ADULT; AGED; AREA UNDER CURVE; CREATININE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE; MALE; MIDDLE AGED; PYRIDINES; SERUM ALBUMIN; STATISTICS, NONPARAMETRIC;

EID: 0032958054     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922007697     Document Type: Article

References (11)

1. Mück W, Ritter W, Ochmann K, Kuhlmann J: Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int J Clin Pharmacol 1997;35:255-260.
2. Steinke W, Yamashita S, Tabei M, Ahr HJ, Beckermann B, Domdey-Bette A, et al: Cerivastatin, a new inhibitor of HMG-CoA reductase: pharmacokinetics in rats and dogs. Jpn Pharmacol Ther 1996;24(Suppl. 9):1217-1237.
3. Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, et al: Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved. Drug Metab Dispos 1997;25:321-331.
4. Bischoff H, Angerbauer R, Boberg M, Schmidt D: Cerivastatin: high enzyme affinity and active metabolites contribute to its high pharmacological activity (abstract). Atherosclerosis 1997;130:25.
5. Krol GJ, Deck GW, Ritter W, Littieri JT: LC separation and induced fluorometric detection of rivastatin in blood plasma. J Pharm Biomed Anal 1993;11:1269-1275.
6. Ulmer HV: Ernährung. In, Schmidt RF, Thews G (eds.): Physiologie des Menschen. Berlin: Springer-Verlag, 1985;628-641.
7. Halstenson CE, Triscari J, De Vault A, Shapiro B, Keane W, Pan H: Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment. J Clin Pharmacol 1992;32:124-132.
8. Stern RH, Yang BB, Horton M, Moore S, Abel RB, Olson SC: Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin. J Clin Pharmacol 1997;37:816-819.
9. Yamazaki M, Aikyama S, Nishigaki R, Sugiyama Y: Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats. Pharm Res 1996;13:1559-1564.
10. Querin S, Lambert R, Cusson JR, Grégoire S, Vickers S, Stubbs RJ, et al: Single-dose pharmacokinetics of 14C-lovastatin in chronic renal failure. Clin Pharmacol Ther 1991;50:437-441.
11. Martin DE, Chapelsky MC, Ilson B, Tenero D, Boike SC, Zariffa N, et al : Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment. J Clin Pharmacol 1998;38:129-137.